Method for the treatment of endotoxic shock in mammal
AssigneeAmerican Cyanamid Company
InventorsAllan Wissner, Suresh S. Kerwar, Constance Kohler
Life of this patent
Estimating the term…
Abstract
The invention is a method of treating endotoxic shock in a mammal which comprises administering to the mammal a therapeutically effective amount of an antagonist to Platelet Activating Factor in combination with a therapeutically effective amount of one or more monoclonal or polyclonal antibodies directed towards either Tumor Necrosis Factor .alpha., Interleukin-1.beta., Gamma Interferon, or bacterial cell wall lipopolysaccharides.
Claims4
A method of treating endotoxic shock in a mammal which comprises administering to the mammal a therapeutically effective amount of an antagonist to Platelet Activating Factor, 3-[[3-[[hydroxy[2-methoxy-3-(tetradecyloxy)phenoxy]phosphinyl]oxy]phenyl]m ethyl]-5-methylthiazolium, hydroxide, inner salt, or 3-[[3-[[hydroxy[2-methoxycarboyl-3-tetradecyloxy)phenoxyl]-phosphinyl]oxy] phenyl]methyl]-5-methyl-thiazolium, hydroxide, inner salt, in combination with a therapeutically effective amount of monoclonal or polyclonal antibodies directed towards bacterial cell wall lipopolysaccharides.
A therapeutic composition comprising an antagonist to Platelet Activating Factor, 3-[[3-[[hydroxy[2-methoxy-3-(tetradecyloxy)phenoxy]-phosphinyl]oxy]phenyl] methyl]-5-methyl-thiazolium, hydroxide, inner salt, or 3-[[3-[[hydroxy[2-methoxycarbolyl-3-(tetradecyloxy)phenoxy]-phosphinyl]oxy ]phenyl]methyl]-5-methylthiazolium, hydroxide, inner salt, in combination with a therapeutically effective amount of monoclonal or polyclonal antibodies directed towards bacterial cell wall lipopolysaccharides.
Dependencies are inferred from the claim text.